CGEN
Compugen Ltd.
$2.14
+8.63% 2026-10-20
Healthcare
CGENSPY
1W
+8.1%
1M
-14.1%
3M
-14.1%
6M
-24.6%
YTD
+39.9%
1Y
+16.3%
Live chart
Loading live chart…
Grades vs sector
MomentumNot enough data yet–
Momentum
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
GrowthNot enough data yet–
Growth
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
ValueNot enough data yet–
Value
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
ProfitabilityNot enough data yet–
Profitability
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
RevisionsNot enough data yet–
Revisions
Not enough data yet
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 5 live models right now.
Quality Growth
not ranked (outside this model's universe or screens)
Momentum Top 15not ranked (outside this model's universe or screens)
Momentum Blendnot in the current book
New Highs Growthnot ranked (outside this model's universe or screens)
Conviction 20not in the current book
News
More newsCompugen to Participate in a Fireside Chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference
PR Newswire · Oct 06
Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor Targets
MarketBeat · Oct 05
Compugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update on October 5, 2026
PR Newswire · Sep 22
Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference
PR Newswire · Sep 08
All You Need to Know About Compugen (CGEN) Rating Upgrade to Buy
Zacks · Aug 31
Key stats
Market cap$202.7M
P/E (trailing)5.6
P/E (forward)-5.8
52-week range1.43 – 3.24
Revenue growth (YoY, latest qtr)+107.0%
Dividend yield0.00%
Analyst consensusStrong Buy (5)
Mean price target$4.60 (+115%)
Valuation and fundamentals
Valuation & fundamentals
No US-GAAP 10-K/10-Q financials in SEC data (foreign filers report on Form 20-F, often under IFRS).
Earnings
Next report: 2026-11-09 · before open · EPS est -0.09
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-03 | -0.08 | -0.07 | +17.6% |
| 2026-05-18 | -0.08 | -0.08 | – |
| 2026-03-02 | 0.14 | 0.60 | +339.0% |
| 2025-11-10 | -0.09 | -0.07 | +22.2% |
| 2025-08-06 | -0.08 | -0.08 | +5.9% |
| 2025-05-19 | -0.05 | -0.08 | -45.5% |
| 2025-03-04 | -0.07 | -0.07 | +6.7% |
| 2024-11-12 | 0.21 | 0.01 | -95.2% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $2.6M | +107.0% |
| 2026-03-31 | $2.2M | – |
| 2025-12-31 | $67.3M | – |
| 2025-09-30 | $1.9M | – |
| 2025-06-30 | $1.3M | – |
Analyst actions
HC Wainwright & Co.
PT $4
2026-10-12 · reit
Buy → BuyPT $4
Leerink Partners
PT $5
2026-05-21 · main
Outperform → OutperformPT $5
Lake Street
PT $6
2026-04-07 · init
→ BuyPT $6
HC Wainwright & Co.
PT $4
2026-01-07 · init
→ BuyPT $4
Truist Securities
PT $4
2024-05-21 · main
Buy → BuyPT $4
Truist Securities
PT $5
2024-03-08 · main
Buy → BuyPT $5
Insider trades
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
Stats refreshed 2026-10-20 18:14:18 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau
Coteau Systematic Strategies publishes stock research and model portfolios. It doesn't manage money or give investment advice. Results are hypothetical unless marked Live. Data: Yahoo Finance (delayed) and SEC EDGAR.